Genome Editing Market Development And Business Intelligence
Summary
- Major factors influencing the growth of the market.
- Leading players & Top Segments.
- Geographic Overview.
Market growth influenced due to following factors-
- Rising government funding and growth in the number of genomics projects.
- High prevalence of infectious diseases and cancer.
- Increasing production of genetically modified crops.
Global market size-
According to research report the global Genome Editing Market is expected to grow at a CAGR of 14.5% to reach to USD 6.28 Billion by 2022.
Leading Players-
Some of the major players in the genome editing market are Thermo Fisher Scientific (US), Merck (Germany), Horizon Discovery Group (UK), GenScript (US), Sangamo BioSciences (US), Integrated DNA Technologies (US), Lonza Group (Switzerland), New England Biolabs (US), OriGene Technologies (US), Transposagen Biopharmaceuticals (US), Editas Medicine (US), and CRISPR Therapeutics (Switzerland).
Top Market Segments-
The technology segment of the genome editing market is classified into CRISPR, TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In, Adenine Base Editor (ADE), and Jump-In). The CRISPR segment is expected to command the largest share of the global genome editing market in 2017.
By end user, the genome engineering market is segmented into biotechnology & pharmaceutical companies, academic & government research institutes, and contract research organizations. The biotechnology & pharmaceutical companies segment is estimated to account for the largest share of the global genome editing market in 2017.
For Details, Download PDF Brochure Here
Geographic Overview -
In 2017, North America is projected to have the highest growth rate during the forecast period. Factors such as the development of gene therapy in the US, increasing use of genetically modified crops, rising prevalence of infectious diseases and cancer, and rising availability of research grants and funding are propelling market growth in North America.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.